Skip to main content
SpringerLink
Log in

Specificity Between the Anti-Aggregatory Actions of Prostacyclin, Prostaglandin E1 And D2 on Platelets

  • Chapter
Mechanisms of Stimulus—Response Coupling in Platelets

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 192))

Abstract

Of the naturally-occurring cyclo-oxygenase metabolites known as the prostaglandins, three such products, prostaglandin E1, prostaglandin D2 and prostacyclin have been demonstrated to exert potent anti-aggregating actions on platelets. Early studies indicated that prostaglandin E1 (PGE1) which is derived from the precursor fatty acid, dihomo-gamma-linoleic acid, could inhibit platelet aggregation in vitro in platelet-rich plasma (PRP) from several species (1,2,3). However, since only trace levels of PGE1 can be detected under normal dietary conditions in vivo (A), the physiological significance of the actions of this prostanoid remain obscure. Later studies with PGD2 (Fig 1) derived from the essential fatty acid arachidonic acid, likewise indicated this prostanoid to be a potent inhibitor of platelet aggregation in human platelet-rich plasma in vitro (5,6). In contrast to PGE1, the activity of PGD2 could not be readily demonstrated in the plasma of the rat or rabbit (7). Thus PGD2 is a potent inhibitor of platelet aggregation in human, sheep and horse platelet-rich plasma but only a weak inhibitor in dog, rabbit, guinea-pig and rat plasma (Table 1). PGD2 can be generated by human platelets and has been detected in human plasma (8,9,10), while the non-enzymatic conversion of the endoperoxide PGH2 to PGD2 is greatly enhanced by the presence of plasma protein from certain species including man (11,12).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. J. Kloeze. Relationship between chemical structure and platelet aggregation activity of prostaglandins. Biochim. Biophys. Acta. 187: 285–292 (1969).

    CAS  Google Scholar 

  2. G. Ball, G.G. Brereton, M. Fulwood, D.M. Ireland and P. Yates. Effect of prostaglandin E1 alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotide including adenosine 3’:5’-cyclic monophosphate. Biochem. J. 120: 709–718 (1970).

    CAS  Google Scholar 

  3. D.C.B. Mills and J.B. Smith. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3’:5’-cyclic monophosphate in platelets. Biochem. J. 121: 185–196 (1971).

    CAS  Google Scholar 

  4. A. Danon, M. Heimberg and J.A. Oates. Enrichment of rat tissue lipids with fatty acids that are prostaglandin precursors. Biochim. Biophys. Acta. 388: 318–330 (1975).

    CAS  Google Scholar 

  5. J.B. Smith, M.J. Silver, C.M. Ingerman and J.J. Kocsis. Prostaglandin D2 inhibits the aggregation of human platelets. Thrombosis Res. 5: 291–299 (1974).

    Article  CAS  Google Scholar 

  6. D.C.B. Mills and D.E. Macfarlane. Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb. Res. 5: 401 (1974).

    Article  CAS  Google Scholar 

  7. B.J.R. Whittle, S. Moncada and J.R. Vane. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandin. 16: 373–388 (1978).

    Article  CAS  Google Scholar 

  8. M. Ali, A.L. Cerskus, J. Zamecnik and J.W.D. McDonald. Synthesis of prostaglandins D2 and thromboxane B2 by human platelets. Thrombosis Res. 11: 485–496 (1977).

    Article  CAS  Google Scholar 

  9. H. Anhut, B.A. Peskar, W. Wachter, B. Grabung and B.M. Peskar. Radioimmunological determination of prostaglandin D2 synthesis in human erythrocytes. Experientia 34: 1494–1496 (1978).

    Article  CAS  Google Scholar 

  10. O. Oelz, R. Oelz and H.R. Knapp. Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets. Prostaglandin 13: 225–234 (1977).

    Article  CAS  Google Scholar 

  11. M. Hamberg and B.B. Fredholm. Isomerization of prostaglandin H2 into prostaglandin D2 in the presence of serum albumin. Biochim. Biophys. Aera. 431: 189–193 (1976).

    CAS  Google Scholar 

  12. E. Christ-Hazelhof, D.H. Nugteren and D.A. van Dorp. Conversion of prostaglandin endoperoxides by glutathione-s-transferases and serum albumins. Biochim. Biophys. Acta. 450: 450–461 (1976).

    CAS  Google Scholar 

  13. S. Moncada and J.R. Vane. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharm. Rev. 30: 293–331 (1979).

    Google Scholar 

  14. S. Moncada. Biological importance of prostacyclin. Br. J. Pharmac. 76: 3–31. (1982).

    CAS  Google Scholar 

  15. S. Moncada, R.J. Gryglewski, S. Bunting and J.R. Vane. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 263: 663–665 (1976).

    Article  CAS  Google Scholar 

  16. B. Cooper and D. Ahem. Characterization of the platelet PGD2receptor. Loss of PGD2 receptors in platelets of patients with myeloproliferative disorders. J. Clin Invest. 64: 586–590 (1979).

    Article  CAS  Google Scholar 

  17. A.M. Siegl, J.B. Smith and M.J. Silver. Specific binding sites for prostaglandin D2 on human platelets. Biochem. Biophys. Res. Comm. 90: 291-296 (1979).

    Article  CAS  Google Scholar 

  18. A.I. Schafer, B. Cooper, D. O’Hara and R.I. Handin. Identification of platelet receptors for prostaglandin I2 and D2. J. Biol. Chem. 254: 2914–2917 (1979).

    CAS  Google Scholar 

  19. A.M. Siegl, J.B. Smith, M.J. Silver, K.C. Nicolaou and D. Ahem. Selective binding site for [3H] prostacyclin on platelets. J. Clin. Invest. 63: 215–220 (1979).

    Article  CAS  Google Scholar 

  20. E. Schillinger and G. Prior. Prostaglandin I2 receptors in a particulate fraction of platelets of various species. Biochem. Pharmacol. 29: 2297–2299 (1980).

    Article  CAS  Google Scholar 

  21. G.L. Shepherd, P.J. Lewis, I.A. Blair, C. de Mey and J. MacDermot. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br. J. Clin. Pharmac. 15: 77–81 (1983).

    CAS  Google Scholar 

  22. M. Lombroso, S. Nicosia, R. Paoletti, B.J.R. Whittle, S. Moncada and J.R. Vane. The use of stable prostaglandins to investigate prostacyclin (PGI2) — binding sites and PGI2 — sensitive adenylate cyclase in human platelet membranes. Prostaglandins. 27: 321–333 (1984).

    Article  CAS  Google Scholar 

  23. S. Hamid and B.J.R. Whittle. Prostaglandin D2 acts as a ‘partial antagonist’ in guinea pig platelets. Br. J. Pharmac. 81: 96P (1984).

    Google Scholar 

  24. H. Bult, E. Wechsung, A. Houvenaghel and A.G. Herman. Prostaglandins E1 and E2, but neither prostacyclin nor prostaglandin D2, have anfi-aggregating activity in chicken blood. Arch. Int. Pharmacodyn. 249: 306–308 (1981).

    CAS  Google Scholar 

  25. D.E. MacIntyre and J.L. Gordon. Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins. Thromb. Res. 11: 705–713 (1977).

    Article  CAS  Google Scholar 

  26. O.V. Miller and R.R. Gorman. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets. J. Pharm. Exptl. Ther. 210: 04–140(1979).

    Google Scholar 

  27. J. Westwick and H. Webb. Selective antagonism of prostaglandin (PG) E1, PGD2 and prostacyclin (PGI2) on human and rabbit platelets by di-4-phloretin phosphate (DPP). Thromb. Res. 12: 973–978 (1978).

    Article  CAS  Google Scholar 

  28. B.J.R. Whittle and S. Moncada. Antithrombotic assessment and clinical potential of prostacyclin analogues, in Progress in Medicinal Chemistry Vol 21, G.P. Ellis and G.B. West, eds, Elsevier Science Publishers, Amsterdam, 237–279 (1984).

    Google Scholar 

  29. D.R. Morton, G.L. Bundy and E.E. Nishizawa. Five-membered ringmodified prostacyclin analogs. In: J.R. Vane, S. Bergstrom, editors. Prostacyclin, New York. Raven Press, p.31, 31–41 (1979).

    Google Scholar 

  30. B.R.J Whittle, S. Moncada, F. Whiting, and J.R. Vane. Carbacyclin-a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 19: 605–627 (1980).

    Article  CAS  Google Scholar 

  31. R. Ceserani, M. Grossoni, D. Longiave, B. Mizzotti, O. Pozzi, A. Dembinska-Kiec and S. Bianco. dl-9a-deoxy-9a-methylene-PGI2 (a stable prostacyclin derivative): preliminary pharmacological data. Prostaqland. Med. 5: 131–139 (1980).

    Article  CAS  Google Scholar 

  32. A. Morita, M. Mori, K. Hasegawa, K. Kojima and S. Kobayashi. Anti-platelet aggregating and disaggregating activities of 6,9-methano PGI2. Life Sci. 27: 695–701 (1980).

    Article  CAS  Google Scholar 

  33. J.W. Aiken and R.J. Shebuski. Comparison in anaesthetised dogs of the anti-aggregatory and hemodynamic effects of prostacyclin and a chemically stable prostacyclin analog, 6a-carba-PGI2 (carbacyclin). Prostaglandins. 19: 629–643 (1980).

    Article  CAS  Google Scholar 

  34. P.G. Adaikan, S.M.M. Karim and L.C. Lau. Platelet and other effects of carboprostacyclin — a stable prostacyclin analogue. Prostaglandins and Med. 5: 307–320 (1980).

    Article  CAS  Google Scholar 

  35. P.G. Adaikan, S.R. Kottegada, L.C. Lau, M.Y. Tai and S.M.M. Karim. Inhibition of platelet aggregation and reversal of vasopressin-induced ECG changes by a carboprostacyclin analogue, ONO 41483, in primates. Prostaqland. Leuk. Med. 9: 307–320 (1982).

    Article  CAS  Google Scholar 

  36. P.G. Adaikan, L.C. Lau, M.Y. Tai and S.M.M. Karim. Inhibition of platelet aggregation with intravenous and oral administration of a carboprostacyclin analogue, 15-eyelopentyl-ω-pentanor-5(E)-carbacyclin (ONO 41483) in man. Prostaqland. Leuk. Med. 10: 53–64 (1983).

    Article  CAS  Google Scholar 

  37. K. Schror, H. Darius, R. Matzky and R. Ohlendorf. The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36374) — Equipotent to PGI2 in vitro. N-S. Arch. Pharmacol. 316: 252–255 (1981).

    Article  CAS  Google Scholar 

  38. K. Schror, R. Ohlendorf and H. Darius. Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia. J. Pharm. Expth Ther. 219: 243–249 (1981).

    CAS  Google Scholar 

  39. J. Casals-Stenzel, M. Buse and W. Losert. Comparison of the vasodepressor action of ZK 36 374, a stable prostacyclin derivative, PGI2 and PGE2 with their effect on platelet aggregation and bleeding time in rats. Prostaqland. Leuk. Med. 10: 197–212 (1983).

    CAS  Google Scholar 

  40. C.A. Gandolfi and R. Ceserani. Prostacyclin analogs: Structure-activity relationships. In: Johnson Hegyeli R, editor: Prostaglandins and Cardiovascular Disease, New York, 1981, Raven Press, p.183–193.

    Google Scholar 

  41. J. Morley, C.P. Page, W. Paul, N. Mongelli, R. Ceserani and C. Gandolfi. A comparative study of PGI2 and two analogues (FCE 21292 and FCE 21258) in vitro and in vivo. Prostaqland. Leuk. Med. 11: 391–399 (1983).

    Article  CAS  Google Scholar 

  42. P.A. Aristoff, P.D. Johnson and A.W. Harrison. Synthesis of 9-substituted carbacyclin analogues. J. Org. Chem. 48: 5341–5348 (1983).

    Article  CAS  Google Scholar 

  43. J. O’Grady, A.M. Hedges, B.J.R. Whittle, L.A.H. Al-Sinawi, Q.A. Mekki, C. Burke, S.G. Moody, M.J. Muti and S. Hassan. A chemically stable analogue, 9β-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man. Br. J. Clin. Pharmac. 18: in press-December (1984).

    Google Scholar 

  44. A.G. Caldwell, C.J. Harris, R. Stepney and N. Whittaker. Hydantoin prostaglandin analogues, potent and selective inhibitors of platelet aggregation. J.C.S. Chem. Comm. 101: 561–562 (1979).

    Article  Google Scholar 

  45. A.G. Caldwell, C.J. Harris, R. Stepney and N. Whittaker. Heterocyclic prostaglandin analogues. Part 2. Hydantoins and other imidazole analogues. J.C.S. Perkin Trans. 1: 495–505 (1980).

    Article  Google Scholar 

  46. B.J.R. Whittle, S. Moncada, K.M. Mullane and J.R. Vane. Platelet and cardiovascular activity of the hydantoin, BW245C, a potent prostaglandin analogue. Prostaglandins. 25: 205–223 (1983).

    Article  CAS  Google Scholar 

  47. M-H. Town, J. Casals-Stenzel and E. Schillinger. Pharmacological and cardiovascular properties of a hydantoin derivative, BW245C, with a high affinity and selectivity for PGD2 receptors. Prostaglandins. 25: 13–28 (1983).

    Article  CAS  Google Scholar 

  48. S.S. Tynan, N.H. Andersen, M.T. Willis, L.A. Harker and S.R. Hanson. On the multiplicity of platelet prostaglandin receptors. II. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogues. Prostaglandins. 27: 683–696 (1984).

    Article  CAS  Google Scholar 

  49. J.E. Tateson, S. Moncada and J.R. Vane. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 13: 389–399 (1977).

    Article  CAS  Google Scholar 

  50. R.R. Gorman, S. Bunting and O.V. Miller. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 13: 377–388 (1977).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Prostaglandin Research, Wellcome Research Laboratories, Langley Court, Beckenham, Kent, BR3 3BS, UK

    B. J. R. Whittle, S. Hamid, P. Lidbury & A. C. Rosam

Authors
  1. B. J. R. Whittle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Lidbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. C. Rosam
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Royal College of Surgeons, London, England

    J. Westwick

  2. Thrombosis Research Unit, King’s College School of Medicine and Dentistry, London, England

    M. F. Scully  & V. V. Kakkar  & 

  3. Department of Pharmacology, University of Glasgow, Glasgow, Scotland

    D. E. MacIntyre

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Plenum Press, New York

About this chapter

Cite this chapter

Whittle, B.J.R., Hamid, S., Lidbury, P., Rosam, A.C. (1985). Specificity Between the Anti-Aggregatory Actions of Prostacyclin, Prostaglandin E1 And D2 on Platelets. In: Westwick, J., Scully, M.F., MacIntyre, D.E., Kakkar, V.V. (eds) Mechanisms of Stimulus—Response Coupling in Platelets. Advances in Experimental Medicine and Biology, vol 192. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9442-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-9442-0_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4615-9444-4

  • Online ISBN: 978-1-4615-9442-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation